September 26, 2025

In a dramatic and uncompromising move, President Donald Trump has unveiled plans for a staggering 100 percent tariff on imported branded and patented pharmaceutical products, set to take effect on October 1, unless pharmaceutical companies commit to building manufacturing plants on American soil. This bold stance follows a recent 25 percent tariff imposed in May and comes as part of Trump’s relentless campaign to rejuvenate American manufacturing and safeguard jobs. The threat of tariffs as high as 200 percent looms over drug manufacturers that refuse to relocate their operations to the United States, raising alarms over a potential surge in medicine prices that could cripple Medicare and Medicaid. With Australia’s CSL being a key player in the US pharmaceutical market, exporting significant quantities of plasma and other health products, the stakes have never been higher as the nation braces for a seismic shift in the pharmaceutical landscape.

Leave a Reply